Journal article

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

M Michael, N Pavlakis, P Clingan, R De Boer, M Johnston, S Clarke

Oncology Reports: an international journal devoted to fundamental and applied research in oncology | SPANDIDOS PUBL LTD | Published : 2012